Amneal Pharmaceuticals (AMRX) financial statements
Amneal Pharmaceuticals reported revenue of $3.0B in fiscal 2025, up 12.8% a year over 9 years.
Net income was $72M and the operating margin 13.1%, against 28.0% in 2016.
Free cash flow was $270M.
The diluted share count rose 155% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Amneal Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $1.0B | $1.7B | $1.6B | $2.0B | $2.1B | $2.2B | $2.4B | $2.8B | $3.0B |
| Cost of revenue | $421M | $507M | $939M | $1.1B | $1.3B | $1.3B | $1.4B | $1.6B | $1.8B | $1.9B |
| Gross profit | $597M | $526M | $716M | $353M | $628M | $769M | $785M | $821M | $1.0B | $1.1B |
| Research and development | $179M | $171M | $194M | $188M | $180M | $202M | $196M | $164M | $191M | $186M |
| Selling, general and admin | $119M | $109M | $228M | $290M | $327M | $366M | $400M | $430M | $476M | $527M |
| Operating income | $285M | $245M | -$20M | -$249M | $91M | $153M | -$95M | $204M | $249M | $394M |
| Pre-tax income | $215M | $171M | -$203M | -$220M | -$36M | $31M | -$248M | -$40M | -$55M | $139M |
| Income tax | $5M | $2M | -$1M | $383M | -$104M | $11M | $7M | $8M | $19M | $11M |
| Net income | $0 | $0 | -$20M | -$362M | $91M | $11M | -$130M | -$84M | -$117M | $72M |
| EPS (diluted) | — | — | -$0.16 | -$2.74 | $0.61 | $0.07 | -$0.86 | -$0.48 | -$0.38 | $0.22 |
| Diluted shares | — | — | 127M | 132M | 149M | 152M | 151M | 176M | 309M | 325M |
| Gross margin | 58.7% | 50.9% | 43.1% | 21.7% | 31.5% | 36.7% | 35.5% | 34.3% | 36.5% | 36.9% |
| Operating margin | 28.0% | 23.7% | -1.2% | -15.3% | 4.6% | 7.3% | -4.3% | 8.5% | 8.9% | 13.1% |
| Net margin | 0.0% | 0.0% | -1.2% | -22.3% | 4.6% | 0.5% | -5.9% | -3.5% | -4.2% | 2.4% |
Balance sheet
Fiscal years, from Amneal Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $27M | $74M | $213M | $151M | $341M | $248M | $26M | $92M | $111M | $282M |
| Receivables | — | $351M | $481M | $604M | $639M | $663M | $742M | — | — | — |
| Inventory | — | $284M | $457M | $381M | $491M | $489M | $531M | $581M | $612M | $606M |
| Total current assets | — | $772M | $1.3B | $1.2B | $1.6B | $1.5B | $1.4B | $1.4B | $1.6B | $1.9B |
| Property, plant and equipment | — | $487M | $544M | $478M | $478M | $514M | $470M | $448M | $425M | $443M |
| Goodwill | $28M | $26M | $426M | $420M | $523M | $593M | $599M | $599M | $597M | $595M |
| Total assets | — | $1.3B | $4.4B | $3.7B | $4.0B | $3.9B | $3.8B | $3.5B | $3.5B | $3.7B |
| Total current liabilities | — | $297M | $554M | $550M | $677M | $677M | $753M | $847M | $1.1B | $882M |
| Long-term debt | — | $1.4B | $2.6B | $2.6B | $2.7B | $2.7B | $2.6B | $2.4B | $2.2B | $2.6B |
| Total liabilities | — | $0 | $3.5B | $3.3B | $3.7B | $3.6B | $3.6B | $3.5B | $3.6B | $3.7B |
| Shareholders' equity | — | $0 | $505M | $232M | $303M | $360M | $298M | $20M | -$109M | -$71M |
| Net debt | -$27M | $1.4B | $2.4B | $2.5B | $2.4B | $2.5B | $2.6B | $2.3B | $2.3B | $2.3B |
Cash flow
Fiscal years, from Amneal Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $115M | $234M | $250M | $2M | $379M | $242M | $65M | $346M | $295M | $340M |
| Capital spending | $123M | $95M | $83M | $47M | $56M | $48M | $46M | $43M | $52M | $70M |
| Free cash flow | -$8M | $139M | $167M | -$45M | $323M | $194M | $19M | $302M | $243M | $270M |
| Stock-based compensation | $0 | $0 | $168M | $22M | $21M | $28M | $32M | $27M | $28M | $32M |
| Dividends paid | $201M | $375M | $183M | $0 | $0 | — | — | — | — | — |
| Net borrowing | — | — | — | — | — | $0 | $0 | $218M | $0 | $2.7B |
| Free cash flow margin | -0.8% | 13.5% | 10.1% | -2.8% | 16.2% | 9.3% | 0.8% | 12.6% | 8.7% | 8.9% |
| Dividends per share | — | — | $1.44 | — | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AMRX.
Open AMRX in InvestinglyQuestions
What was Amneal Pharmaceuticals's revenue in 2025?
$3.0B in fiscal 2025, from its 10-K filing.
How much free cash flow does Amneal Pharmaceuticals generate?
$270M in fiscal 2025 (operating cash flow minus capital spending).
From Amneal Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.